Merck KGaA, operating under the OTCMKTS:MKGAF ticker, is a leading science and technology company headquartered in Darmstadt, Germany. Founded in 1668, the firm remains majority-owned by the founding Merck family and has grown from a small pharmacy into a global enterprise. Its activities span three core business sectors—Healthcare, Life Science and Performance Materials—serving customers in pharmaceuticals, biotechnology, electronics and specialty chemicals.
In its Healthcare division, Merck KGaA develops and markets prescription medicines in areas such as oncology, immuno-inflammation and fertility. The company’s research and development focus includes targeted cancer therapies, emerging immunotherapies and innovative treatment options for women’s health. Clinical studies are conducted at multiple sites worldwide, reflecting Merck KGaA’s commitment to advancing patient care and expanding its therapeutic pipeline.
The Life Science segment provides tools, consumables and services for biopharmaceutical research, diagnostics and production. Offerings include laboratory reagents, single-use technologies and bioprocess solutions designed to accelerate drug development and manufacturing. In parallel, the Performance Materials arm delivers high-tech solutions for semiconductor manufacturing, consumer electronics and surface treatment, supplying specialty chemicals, liquid crystals for displays and ultraviolet curable resins.
With operations in over 60 countries and production facilities on four continents, Merck KGaA combines a global footprint with a decentralized management structure. Under the leadership of Chief Executive Officer Belén Garijo and an executive board drawn from diverse scientific and commercial backgrounds, the company emphasizes sustainable growth, strategic partnerships and digital transformation. Its broad geographic reach and diversified portfolio position Merck KGaA as a prominent player in multiple high-growth industries.
AI Generated. May Contain Errors.